Trials / Unknown
UnknownNCT01530711
Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Pere Gines · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terlipressin and albumin | Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%. Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2012-02-10
- Last updated
- 2016-08-18
Locations
6 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01530711. Inclusion in this directory is not an endorsement.